company background image
PLX logo

Protalix BioTherapeutics TASE:PLX Stock Report

Last Price

₪7.33

Market Cap

₪407.5m

7D

-0.1%

1Y

97.5%

Updated

23 Mar, 2023

Data

Company Financials +

Protalix BioTherapeutics, Inc.

TASE:PLX Stock Report

Market Cap: ₪407.5m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

PLX Stock Overview

A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

PLX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Protalix BioTherapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Protalix BioTherapeutics
Historical stock prices
Current Share PriceUS$7.33
52 Week HighUS$7.80
52 Week LowUS$3.15
Beta1.47
11 Month Change28.98%
3 Month Change75.79%
1 Year Change97.55%
33 Year Change-16.86%
5 Year Change-59.71%
Change since IPO-97.70%

Recent News & Updates

Recent updates

Shareholder Returns

PLXIL BiotechsIL Market
7D-0.1%-4.3%-1.3%
1Y97.5%-17.1%-4.0%

Return vs Industry: PLX exceeded the IL Biotechs industry which returned -49.3% over the past year.

Return vs Market: PLX exceeded the IL Market which returned -25.9% over the past year.

Price Volatility

Is PLX's price volatile compared to industry and market?
PLX volatility
PLX Average Weekly Movement9.4%
Biotechs Industry Average Movement6.7%
Market Average Movement4.3%
10% most volatile stocks in IL Market8.2%
10% least volatile stocks in IL Market3.2%

Stable Share Price: PLX's share price has been volatile over the past 3 months.

Volatility Over Time: PLX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

FoundedEmployeesCEOWebsite
1993195Dror Bashanwww.protalix.com

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases.

Protalix BioTherapeutics, Inc. Fundamentals Summary

How do Protalix BioTherapeutics's earnings and revenue compare to its market cap?
PLX fundamental statistics
Market cap₪407.53m
Earnings (TTM)-₪54.09m
Revenue (TTM)₪172.62m

2.4x

P/S Ratio

-7.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PLX income statement (TTM)
RevenueUS$47.64m
Cost of RevenueUS$19.59m
Gross ProfitUS$28.05m
Other ExpensesUS$42.97m
Earnings-US$14.93m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin58.87%
Net Profit Margin-31.33%
Debt/Equity Ratio-264.9%

How did PLX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.